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Abstract
Background: Molecular biomarkers that might help to distinguish between more aggressive and clinically
insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular
alteration in PCa seems to be a promising source for such biomarkers. In this study, PITX3 DNA methylation
(mPITX3) and its potential role as a prognostic biomarker were investigated. Furthermore, mPITX3 was analyzed in
combination with the established PCa methylation biomarker PITX2 (mPITX2).
Methods: mPITX3 and mPITX2 were assessed by a quantitative real-time PCR and by means of the Infinium
HumanMethylation450 BeadChip. BeadChip data were obtained from The Cancer Genome Atlas (TCGA) Research
Network. DNA methylation differences between normal adjacent, benign hyperplastic, and carcinomatous prostate
tissues were examined in the TCGA dataset as well as in prostatectomy specimens from the University Hospital
Bonn. Retrospective analyses of biochemical recurrence (BCR) were conducted in a training cohort (n = 498) from
the TCGA and an independent validation cohort (n = 300) from the University Hospital Bonn. All patients received
radical prostatectomy.
Results: In PCa tissue, mPITX3 was increased significantly compared to normal and benign hyperplastic tissue. In
univariate Cox proportional hazards analyses, mPITX3 showed a significant prognostic value for BCR (training cohort:
hazard ratio (HR) = 1.83 (95 % CI 1.07–3.11), p = 0.027; validation cohort: HR = 2.56 (95 % CI 1.44–4.54), p = 0.001). A
combined evaluation with PITX2 methylation further revealed that hypermethylation of a single PITX gene member
(either PITX2 or PITX3) identifies an intermediate risk group.
Conclusions: PITX3 DNA methylation alone and in combination with PITX2 is a promising biomarker for the risk
stratification of PCa patients and adds relevant prognostic information to common clinically implemented
parameters. Further studies are required to determine whether the results are transferable to a biopsy-based patient
cohort. Trial registration: Patients for this unregistered study were enrolled retrospectively.
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Background
Prostate cancer (PCa) is the most common cancer in
men in the western hemisphere. In 2015, 220,800 new
cases and 27,540 tumor-related deaths were predicted
for the USA [1]. In the last couple of decades, prostate-
specific antigen (PSA) screening has increased the num-
ber of early detected PCa [2]. However, the natural
course of these tumors is highly variable. A majority of
cases progresses slowly, remains years to decades in a
clinically dormant state, and may be safely kept under
active surveillance. Others develop fast and lead to lo-
cally aggressive growth and metastasis after short
courses of disease. In the long run, these patients might
benefit from a more radical treatment when diagnosed
at a very early stage. Clinicopathological parameters, i.e.,
PSA values, tumor size, number of positive biopsies, and
Gleason grading groups, as suggested by the Inter-
national Society of Urological Pathologists (ISUP), guide
the decision-making process when determining whether
a patient may benefit from radical prostatectomy or can
instead be closely monitored. However, in many cases,
this approach has not proven satisfactory in that patients
either suffered from overtreatment or experienced very
early PSA relapses after surgery [3, 4]. Therefore, new
prognostic tools are still urgently needed to distinguish
between the aggressive and indolent subtypes of PCa.
As potential biomarkers, epigenetic modifications such
as hyper- or hypomethylation of tumor-related genes
have lately emerged as one of the key alterations in can-
cer development [5–7]. Aberrant patterns of methylation
have aroused interest in the molecular subclassification
of urologic tumors and might potentially serve as prog-
nostic and predictive biomarkers in PCa [8, 9]. Further-
more, DNA is a highly robust cellular element that can
be extracted reliably from different materials, e.g., fresh
tissue, formalin-fixed paraffin-embedded tissue (FFPET),
and body fluids [10, 11].
Methylation of the paired-like homeodomain tran-
scription factor 2 (PITX2) has been successfully proven
a powerful prognostic biomarker in several cancer en-
tities such as lung cancer [12], hormone-receptor-
negative breast cancer [13–16], and PCa [17–19]. PITX2
is initiated by Wnt/β-catenin and is involved in the con-
trol of cell proliferation [20]. PITX2 regulates the ex-
pression of the androgen receptor (AR) and insulin-like
growth factor (IGF) receptor genes, leading to the regu-
lation of signaling pathways involving AR and IGF dur-
ing PCa progression [21].
The paired-like homeodomain transcription factor 3
or pituitary homeobox 3 (PITX3) is a transcription factor
belonging to the same protein family as PITX2 [22].
PITX3 has been shown to be transiently expressed in
the eye lens and skeletal muscle during embryogenesis
[23, 24]. Very recently, it has been reported that
exposure to environmental xenoestrogens may lead to
neonatal DNA methylation re-programing effects in the
prostate including dysregulation of PITX3 methylation
[25]. This may potentially foster carcinogenesis. More-
over, PITX3 has previously been found to be aberrantly
methylated in breast cancer patients [26].
These findings prompted us to investigate PITX3
promoter methylation in PCa in a publically available
dataset from The Cancer Genome Atlas (TCGA) [27]
(training cohort) and an independent primary PCa pa-
tient cohort from the University Hospital Bonn (valid-
ation cohort).
Results
PITX3 and PITX2 promoter methylation in prostate tissues
from TCGA training cohort
For the analysis of PITX3 promoter methylation
(mPITX3) in the training cohort, results obtained from
two Illumina Infinium HumanMethylation450 BeadChip
beads from the TCGA dataset (cg12324970 and
cg23095743) were used. Both beads were located within
the CpG island of PITX3 (Fig. 1a). Firstly, PCa (n = 498)
and normal adjacent tissue (NAT, n = 50) samples from
the training cohort were analyzed with respect to mPITX3.
Patient samples showed a significantly lower level of
mPITX3 in NAT compared to PCa samples (p < 0.001,
Fig. 2a). A histogram of mPITX3 showed a bell curve with
a minor depression at ≈68 % (Fig. 3a). mPITX3 levels as a
continuous variable were related to prognostic clinicopath-
ological variables and were found to be significantly corre-
lated with the ISUP Gleason grading group (ρ = 0.112;
p = 0.012), pathologic tumor (pT) category (ρ = 0.123;
p = 0.006), presurgical PSA (ρ = 0.134; p = 0.003), and
the AR activity score (ρ = 0.154; p = 0.005) as obtained
from TCGA [27] in the training cohort. In order to
analyze the suitability of mPITX3 for the stratification
of patients at risk for biochemical recurrence (BCR),
mPITX3 was dichotomized by an optimized cutoff
(mPITX3low < 68.2 % ≤mPITX3high; Table 1) which was
identified by an iterative approach. In the training cohort,
mPITX3high was significantly associated with BCR in the
univariate Cox proportional hazards model (hazard ratio
(HR) = 1.83 (95 % CI 1.07–3.11); p = 0.027; (Table 2)) and
the Kaplan-Meier analysis (likelihood ratio (LR) = 5.05;
p = 0.025, Fig. 3b).
PITX3 carries a homeodomain which is highly homolo-
gous with PITX2 [28]. In a second step, PITX2 promoter
methylation (mPITX2) was therefore analyzed in an
equivalent manner. A PITX2 quantitative methylation-
specific real-time polymerase chain reaction (PCR)
(qMSP) assay has been established and validated in a pre-
vious study using other patient material [29]. Three beads
from the HumanMethylation450 BeadChip which are lo-
cated in close proximity of the established qMSP assay
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were selected. mPITX2 showed a rather asymmetrical dis-
tribution (Fig. 3c). Associations of mPITX2 levels with clin-
icopathological variables in the training cohort are shown
in Table 3. In brief, mPITX2 levels correlated with age, T
category, ISUP Gleason grading group, surgical margin,
and ETS-related gene (ERG) fusion status. Dichotomization
by an optimized cutoff (mPITX2low < 34.3 % ≤mPITX2high)
revealed a significant prognostic value. In the training co-
hort, mPITX2high was significantly associated with BCR in
the univariate Cox proportional hazards model (HR = 2.20
(95 % CI 1.25–3.87); p = 0.006) and the Kaplan-Meier ana-
lysis (LR = 7.95; p = 0.005, Fig. 3d).
Since both parameters showed excellent prognostic
performance, the combination of mPITX2 and mPITX3
was tested in the TCGA collective. Here, mPITX2low and
mPITX3low cases showed significantly longer BRC-free
survival compared to patients with mPITX2high and/or
mPITX3high (LR = 12.70, p = 0.002; Fig. 4a).
Analytical assay design and performance of the mPITX3
real-time PCR
Following the analysis of the training cohort, a PITX3
quantitative methylation (QM) assay was designed
within the CpG island upstream of the PITX3 gene in
the same region as the beads selected from the
HumanMethylation450 BeadChip analyzed by TCGA
Research Network (Fig. 1a). In contrast to the estab-
lished qMSP used to quantify PITX2 methylation as
described earlier [29], QM assay refers to an assay
which is based on two primers which do not cover any
CpG sites and therefore amplify unmethylated as well
as methylated DNA. This assay contains two detection
Fig. 2 PITX3 DNA methylation in prostatectomy specimens. Median methylation is indicated by the gray line. PITX3 DNA methylation is significantly
higher in prostate cancer (PCa) tissue compared to corresponding normal adjacent tissue (NAT) and benign prostatic hyperplasia (BPH). a NAT and PCa
samples of the training cohort (TCGA). p values refer to Wilcoxon-Mann-Whitney test. b NAT, BPH, and PCa samples from a test study comprising 71
patient samples. Each sample was measured in triplicate. p values refer to Kruskal-Wallis test
Fig. 1 Genomic location, design, and validation of the PITX3 QM Assay. a PITX3 quantitative-methylation (QM) assay located on the reverse strand
of chromosome 10. Both PITX3 splice variants PITX3-001 and PITX3-201 are shown. The information was taken from Ensembl Homo sapiens version
82.38 (GRCh38.p3). The two beads of the Illumina Infinium HumanMethylation450 BeadChip (cg12324970 and cg23095743) used from the TCGA
dataset are shown. The GC content (%) is shown with the dashed line indicating 50 % GC. b The QM real-time PCR assay was validated on a
dilution series of bisulfite-converted artificially methylated and unmethylated DNA. Each sample was measured in duplicate
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Fig. 3 Frequency and prognostic value of mPITX3 and mPITX2 in the training (n = 498) and validation (n = 300) cohorts. PITX3 and PITX2 DNA
methylation was analyzed in prostate carcinoma patients from two cohorts. Methylation frequencies (a, c, and e) and Kaplan-Meier analyses of
BCR-free survival in patients stratified according to dichotomized mPITX3 and mPITX2 levels are shown (b, d, and f). a mPITX3 analysis in the
training cohort revealed a symmetric, bell-shaped distribution covering a broad spectrum of values (22–92 %). An optimal cutoff was elaborated
by an iterative approach (68.2 %) stratifying patients into mPITX3 hyper- (mPITX3high) and hypomethylated (mPITX3low) cases. b Patient survival in
the training cohort according to mPITX3low and mPITX3high status. Patients with mPITX3low tumors show a better prognosis. Approximate mean
BCR-free survival: 93 months (mPITX3low, 95 % CI 85–100 months, n = 301) and 76 months (mPITX3high, 95 % CI 63–90 months, n = 117; LR = 5.05;
p = 0.025), respectively. c mPITX2 analysis in the training cohort revealed an uneven distribution covering an altogether lower spectrum of values
than mPITX3 (5–79 %). An optimal cutoff was elaborated by an iterative approach (34.3 %) stratifying patients into mPITX2 hyper- (mPITX2high) and
hypomethylated (mPITX2low) cases. d Patient survival in the validation cohort according to mPITX2low and mPITX2high status. Patients with mPITX2low
tumors show a better prognosis. Approximate mean BCR-free survival: 96 months (mPITX2low, 95 % CI 88–105 months, n = 220) and 78 months
(mPITX2high, 95 % CI 67–89 months, n = 198; LR = 7.95; p = 0.005), respectively. e mPITX3 analysis in the validation cohort revealed a flattened,
bell-shaped distribution covering (5–100 %). An optimal cutoff was elaborated by an iterative approach (61.8 %) stratifying patients into mPITX3 hyper-
(mPITX3high) and hypomethylated (mPITX3low) cases. f Patient survival in the validation cohort according to mPITX3low and mPITX3high status. Patients
with mPITX2low tumors show a better prognosis. Approximate mean BCR-free survival: 125 months (mPITX3low, 95 % CI 118–132 months, n = 145) and
103 months (mPITX3high, 95 % CI 91–115 months, n = 105; LR = 11.17; p = 0.001), respectively. Patient survival in the validation cohort according to
mPITX2low and mPITX2high status is reported elsewhere [30]
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Table 1 Associations of PITX3 DNA methylation (mPITX3) with clinicopathological parameters of PCa patients from the training (n = 498) and validation cohort (n = 300)
Training cohort Validation cohort
Patients (n) Median mPITX3 (%) mPITX3low mPITX3high p value Patient (n) Median mPITX3 (%) PITX3low mPITX3high p value
All patients 498 (100 %) 62.0 300 (100 %) 57.9
Mean/median follow-up (months) 22/16 66/63
Age (years) 0.021a 0.011a
≤60 224 (45.0 %) 60.2 166 (73.8 %) 58 (25.8 %) 71 (23.7 %) 50.0 48 (64.0 %) 23 (30.7 %)
>60 274 (55.0 %) 62.9 184 (66.9 %) 90 (32.7 %) 219 (73.0 %) 61.0 115 (51.3 %) 104 (46.4 %)
Unknown 0 (0.0 %) 10 (3.3 %)
T category 0.017a <0.001a
pT1/2 188 (37.8 %) 59.6 147 (78.2 %) 41 (21.8 %) 198 (66.0 %) 53.4 128 (62.4 %) 70 (34.1 %)
pT3/4 293 (58.8 %) 63.3 189 (64.1 %) 104 (35.3 %) 88 (29.3 %) 69.0 32 (35.6 %) 56 (62.2 %)
Unknown 17 (3.4 %) 14 (4.7 %)
ISUP Gleason grading group 0.035b 0.029b
1 (<7) 45 (9 %) 61.6 33 (73.3 %) 12 (26.7 %) 155 (51.7 %) 53.1 99 (60.7 %) 56 (34.4 %)
2 (3 + 4) 147 (29.5 %) 59.5 118 (79.2 %) 29 (19.5 %) 53 (17.7 %) 58.5 29 (54.7 %) 24 (45.2 %)
3 (4 + 3) 101 (20.3 %) 62.1 67 (66.3 %) 34 (33.7 %) 23 (7.7 %) 69.0 10 (43.5 %) 13 (56.5 %)
4 (=8) 64 (12.9 %) 61.0 34 (67.2 %) 21 (32.8 %) 34 (11.3 %) 61.1 17 (48.6 %) 17 (48.6 %)
5 (>8) 141 (28.3 %) 64.1 89 (63.1 %) 52 (36.9 %) 15 (5.0 %) 66.4 3 (18.8 %) 12 (75.0 %)
Unknown 0 (0.0 %) 20 (6.7 %)
Surgical margin 0.19a 0.62a
R0 318 (63.9 %) 60.2 227 (71.4 %) 89 (28.0 %) 198 (66.0 %) 55.3 117 (49.1 %) 74 (37.4 %)
R1 152 (30.5 %) 63.5 103 (67.8 %) 49 (32.2 %) 96 (32.0 %) 62.7 44 (45.8 %) 50 (52.1 %)
Unknown 28 (5.6 %) 6 (2.0 %)
Nodal status 0.75a 0.66a
pN0 349 (70.1 %) 61.7 243 (69.8 %) 103 (29.6 %) 279 (93.0 %) 57.5 152 (54.5 %) 117 (41.9 %)
pN1 79 (15.8 %) 61.6 55 (69.6 %) 24 (30.4 %) 17 (5.7 %) 61.7 9 (52.9 %) 8 (47.1 %)
Unknown 70 (14.1 %) 4 (1.3 %)
Pre-surgical PSA (ng/ml) 0.051b 0.089b
0–4 53 (10.6 %) 60.0 39 (73.4 %) 14 (26.4 %) 24 (8.70 %) 49.4 19 (70.4 %) 5 (18.5 %)
4–10 286 (57.5 %) 60.5 210 (73.4 %) 76 (26.6 %) 169 (56.3 %) 58.3 95 (54.9 %) 74 (42.8 %)
>10 156 (31.3 %) 64.0 98 (62.0 %) 58 (36.7 %) 84 (28.0 %) 61.0 43 (49.4 %) 41 (47.1 %)











Table 1 Associations of PITX3 DNA methylation (mPITX3) with clinicopathological parameters of PCa patients from the training (n = 498) and validation cohort (n = 300)
(Continued)
ERG fusionc 0.58a 0.15a
Negative 178 (35.8 %) 61.7 125 (70.2 %) 53 (29.8 %) 164 (54.7 %) 68.9 65 (44.5 %) 74 (50.7 %)
Positive 152 (30.5 %) 62.9 106 (69.7 %) 46 (30.3 %) 56 (18.7 %) 65.7 27 (41.5 %) 35 (53.8 %)
Unknown 168 (33.7 %) 80 (26.7 %)
AR score 0.35a 0.32a
Negative 246 (49.4 %) 61.4 124 (74.7 %) 42 (25.3 %) 83 (27.7 %) 68.95 40 (48.2 %) 40 (48.2 %)
Positive 84 (16.9 %) 64.5 109 (35.3 %) 58 (34.7 %) 81 (27.0 %) 68.5 46 (56.8 %) 34 (42.0 %)
Unknown 186 (33.7 %) 136 (45.3 %)
mPITX3 was dichotomized by the respective optimized cutoff into mPITX3low vs. mPITX3high
aWilcoxon-Mann-Whitney test
bKruskal-Wallis test











probes: One detection probe specifically binds to
unmethylated DNA while the other probe specifically
and competitively binds to methylated DNA. The assay
performance was validated using a dilution series of
bisulfite-converted artificially methylated and unmethy-
lated DNA. The assay allowed for an accurate quantifica-
tion of mPITX3 within the whole spectrum from 0 to
100 % methylation (r2 = 0.98, Fig. 1b).
PITX3 promoter methylation in prostate tissues in the test
study
In order to avoid artifacts which might result from a
genome-wide methylation testing approach as used by
the TCGA, the aforementioned findings from the
TCGA cohort were confirmed in a small test study
comprised of 71 samples from 25 prostatectomy speci-
mens. mPITX3 levels were significantly lower in NAT
and samples with benign prostatic hyperplasia (BPH)
compared to PCa samples (p < 0.001, Fig. 2b). No differ-
ence of mPITX3 was detected in BPH compared to
NAT samples.
PITX3 promoter methylation in prostate tissues from the
validation cohort
In a validation cohort of 300 patients with clinical
follow-up, mPITX3 significantly correlated with the
ISUP Gleason grading group (ρ = 0.193; p = 0.001), pT
(ρ = 0.278; p < 0.001), and pre-surgical PSA (ρ = 0.143;
p = 0.017). Associations of mPITX2 with clinicopathologic
parameters in the validation cohort have been described
elsewhere [30]. In a histogram, the distribution of mPITX3
resembled a flattened bell-shaped curve dichotomized by
an optimized cutoff (mPITX3low < 61.8 % ≤mPITX3high;
Fig. 3e). In concordance with the training cohort,
mPITX3high was significantly associated with early BCR
using an optimized cutoff (HR = 2.56 (95 % CI 1.44–
4.54); p = 0.001, Table 2). This result was further con-
firmed by Kaplan-Meier analysis (LR = 11.17; p = 0.001;
Fig. 3f ). Additionally, mPITX3 was significantly associ-
ated with BCR in the univariate Cox proportional haz-
ards model when analyzed as continuous variable
without cutoff-based dichotomization (HR = 1.02 (95 %
CI 1.00–1.03), p = 0.025).
Since combined mPITX2 and mPITX3 revealed signifi-
cant additive prognostic information in the training co-
hort, the combination of mPITX2 and mPITX3 was also
tested in the validation cohort. According to the results
obtained from the training cohort, mPITX2low and
mPITX3low cases showed significantly longer BRC-free
survival compared to patients with mPITX2high and/or
mPITX3high (LR = 12.14, p = 0.002; Fig. 4b).
Discussion
In this study, PITX3 was shown to be aberrantly methyl-
ated in prostate carcinomas. PITX3 was hypermethylated
in PCa compared to normal adjacent prostate tissue in
the training cohort and compared to both normal and
benign prostatic hyperplasia in the test study. These
findings are in line with previous reports on PITX3
methylation in breast carcinoma [26].
Furthermore, carcinomatous PITX3 hypermethylation
was significantly associated with established clinicopath-
ologic parameters characteristic of PCa. In detail, high
ISUP Gleason grading group, advanced tumor stages,
and high preoperative PSA values were related to high
PITX3 methylation in both cohorts. In addition, PITX3
methylation correlated with a molecular AR activity
score as obtained from TCGA Research Network [27],
Table 2 Univariate Cox proportional hazard analysis of BCR-free survival in the training and validation cohort including PCa patients
treated by radical prostatectomy
Training cohort Validation cohort
Clinicopathological parameters/biomarker n Hazard ratio (95 % CI) p value n Hazard ratio (95 % CI) p value
Age 411 1.02 (0.98–1.06) 0.39 259 1.01 (0.96–1.06) 0.70
Tumor stage (pT3 and pT4 vs. pT2 and pT1) 346 4.25 (2.37–7.61) <0.001 260 2.07 (1.30–3.30) 0.001
ISUP Gleason grading group 411 1.69 (1.34–2.13) <0.001 252 1.99 (1.63–2.42) <0.001
Surgical margin (R1 vs. R0) 389 1.49 (0.87–2.56) 0.15 258 1.00 (0.98–1.02) 0.84
Nodal status (pN1 vs. pN0) 357 1.84 (1.00–3.36) 0.048 259 1.09 (0.50–2.41) 0.82
Preoperative PSA level 409 1.04 (1.02–1.05) <0.001 250 1.01 (1.00–1.02) 0.11
AR activity score (positive vs. negative) 271 0.74 (0.32–1.71) 0.49 NA NA NA
AR protein expression (AR high vs. AR low) NA NA NA 143 0.82 (0.40–1.70) 0.60
ERGa (ERG-fusion positive vs. ERG-fusion negative) 271 0.80 (0.40–1.57) 0.51 182 0.78 (0.40–1.51) 0.46
mPITX3 (optimized cutoff, mPITX3high vs. mPITX3low) 411 1.83 (1.07–3.11) 0.027 250 2.56 (1.44–4.54) 0.001
Only patients with available follow-up were included into this analysis
NA not analyzed
aTraining cohort: ERG-fusion as adopted from The Cancer Genome Atlas Research Network (2015) [27]; validation cohort: nuclear ERG protein expression as
surrogate marker for ERG-translocation
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Table 3 Associations of PITX2 DNA methylation (mPITX2) with clinicopathological parameters of PCa patients from the training
cohort (n = 498)
Patients (n) Median mPITX2 (%) mPITX2low mPITX2high p value
All patients 498 (100 %) 32.9
Mean/median follow-up (months) 22/16
Age (years) 0.001a
≤60 224 (45.0 %) 31.0 128 (57.1 %) 96 (42.9 %)
>60 274 (55.0 %) 35.2 135 (49.1 %) 140 (50.9 %)
Unknown 0 (0.0 %)
T category 0.043a
pT1/2 188 (37.8 %) 25.7 137 (70.3 %) 58 (29.7 %)
pT3/4 293 (58.8 %) 37.5 126 (41.4 %) 178 (58.6 %)
Unknown 17 (3.4 %)
ISUP Gleason grading group <0.001b
1 (<7) 45 (9 %) 28.0 31 (68.9 %) 14 (31.1 %)
2 (3 + 4) 147 (29.5 %) 28.6 95 (64.2 %) 53 (35.8 %)
3 (4 + 3) 101 (20.3 %) 31.5 55 (54.5 %) 46 (45.5 %)
4 (=8) 64 (12.9 %) 34.1 33 (51.6 %) 31 (48.4 %)
5 (>8) 141 (28.3 %) 41.0 49 (34.8 %) 92 (65.2 %)
Unknown 0 (0.0 %)
Surgical margin <0.001a
R0 318 (63.9 %) 30.8 180 (56.8 %) 137 (43.2 %)
R1 152 (30.5 %) 37.0 68 (44.7 %) 84 (55.3 %)
Unknown 28 (5.6 %)
Nodal status 0.19a
pN0 349 (70.1 %) 32.3 184 (53.0 %) 163 (47.0 %)
pN1 79 (15.8 %) 36.6 32 (40.5 %) 47 (49.5 %)
Unknown 70 (14.1 %)
Pre-surgical PSA (ng/ml) 0.36b
0–4 53 (10.6 %) 29.5 31 (58.5 %) 122 (41.5 %)
4–10 286 (57.5 %) 32.9 150 (52.4 %) 136 (47.6 %)
>10 156 (31.3 %) 34.3 79 (50.3 %) 78 (49.7 %)
Unknown 3 (0.6 %)
ERG fusionc <0.001a
Negative 178 (35.8 %) 28.0 122 (62.9 %) 66 (37.1 %)
Positive 152 (30.5 %) 37.2 69 (45.4 %) 83 (54.6 %)
Unknown 168 (33.7 %)
AR score 0.15a
Negative 246 (49.4 %) 30.6 140 (56.9 %) 106 (43.1 %)
Positive 84 (16.9 %) 34.6 41 (48.8 %) 43 (51.2 %)
Unknown 186 (33.7 %)
mPITX2 in the validation cohort is described elsewhere [30]. mPITX2 was dichotomized by the respective optimized cutoff into mPITX2low vs. mPITX2high
aWilcoxon-Mann-Whitney test
bKruskal-Wallis test
cERG fusion status as adopted from The Cancer Genome Atlas Research Network (2015) [27]
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which was only available for the training cohort. An as-
sociation with the ERG fusion protein or ERG protein
expression could not be determined. Recently, dysregula-
tion of PITX3 methylation has been linked to the envir-
onmental burden of xenoestrogens [25]. In this respect,
PITX3 methylation may have an exceptional position
among prognostic biomarkers. Of note, PITX3 methyla-
tion served as a prognostic biomarker for BCR in both
the training and validation cohort of radical prostatec-
tomy patients. In Kaplan-Meier analysis, high PITX3
methylation defined by an optimized cutoff for both pa-
tient groups was associated with a shorter BCR-free sur-
vival in the training and validation cohort. As a limiting
condition, however, the follow-up period was shorter in
the training cohort compared to the validation cohort,
and the training cohort comprised significantly more
high-grade carcinomas with an advanced stage and asso-
ciated with earlier BCR. In the validation cohort, PITX3
methylation succeeded as a prognostic factor dichoto-
mized by an optimized cutoff and as a continuous vari-
able in the univariate Cox proportional hazards analysis.
In consideration of the fact that several recent studies
have reported on a striking prognostic power of gene
methylation of PITX2 [17, 19], a close relative of PITX3,
a combined analysis of PITX2 and PITX3 promoter
methylation, was performed. Thereby, we intended to in-
vestigate possible interactions to compensate for gene
methylation in either PITX member. Combined analysis
of PITX2 and PITX3 promoter methylation revealed that
low methylation in both genes was associated with favor-
able courses of disease in each cohort. Vice versa,
patients with hypermethylated PITX2 and PITX3 pro-
moters presented with the shortest BCR-free survival
intervals after radical prostatectomy. Intermediate BRC-
free survival intervals were observed in patients with low
gene methylation in one PITX member and high methy-
lation in the other PITX members. In respect thereof, we
conclude that the analysis of PITX3 gene methylation
adds to the prognostic information obtained from PITX2
analysis, suggesting that, in contrast to their overlapping
functions in human development, they play a distinct
role in the genesis and progression of PCa. This issue
further needs to be confirmed in larger studies in which
patient numbers allow for multivariate analysis. Further-
more, the prognostic value should be analyzed with re-
gard to more clinically relevant endpoints, i.e., prostate
cancer-specific survival, which unfortunately was not
available for the present analyses.
The present study indicates that PITX3 promoter
methylation may be of great value for the tailoring of in-
dividual therapies and risk stratification. Even though
PSA screening has led to a reduction of cases with ad-
vanced disease and disease-specific mortality, low-risk
PCa rarely causes symptoms or affects survival if left un-
treated. Nevertheless, most men diagnosed with low-risk
PCa in the USA receive up-front treatment, including
prostatectomy or radiotherapy [31]. Hence, the early
detection of low-risk PCa may lead to overdiagnosis
resulting in overtreatment of patients with potential un-
necessary side effects such as urinary dysfunction or im-
potence [3, 4]. The present study combines the analysis
of PITX3 promoter methylation in two independent
Fig. 4 Survival according to combined mPITX3 and mPITX2 status. Kaplan-Meier analysis of BCR-free survival in prostate cancer patients stratified
according to PITX3 and PITX2 DNA methylation status. Training cohort (n = 498, a): After a homogenous dropout within the first months after
prostatectomy in all three groups, patients with low methylation values in PITX2 and PITX3 genes show the lowest number of BCR events
(n = 182). Patients with high methylation in PITX2 and PITX3 genes present with the highest rate of BCR events (n = 67). Intermediate numbers
of BCR events are observed in patients with low methylation in one PITX gene member and high methylation in the other PITX gene member
(n = 169). Validation cohort (n = 300, b): Patients with low methylation values in PITX2 and PITX3 genes show the lowest number of BCR events
(n = 136). Patients with high methylation in PITX2 and PITX3 genes present with the earliest BCR events (n = 32). Patients with low methylation
in one PITX gene member and high methylation in the other PITX gene member (n = 82) show the highest number of BCR events, however,
more protracted than patients with high methylation in both PITX genes
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cohorts and by two different molecular assays; however,
further studies are warranted to scrutinize the potential
of PITX3 methylation as a biomarker prior to radical
prostatectomy. Therefore, the assay’s prognostic power
needs to be evaluated in biopsies from PCa patients in-
cluded in an active surveillance protocol.
Conclusions
In summary, PITX3 DNA methylation is a promising
biomarker for the risk stratification of PCa patients and
adds relevant prognostic information to the common clin-
ically implemented parameters. The prognostic power of
PITX3 DNA methylation was validated in two independ-
ent radical prostatectomy cohorts. Adjunct to the analysis
of PITX2 promoter methylation, hypermethylation of
PITX3 provided supplemental information on the course
of disease, indicating adverse patient outcome. This im-
plies a distinct function of the PITX3 gene in the develop-
ment of PCa. However, the establishment of PITX3 as a
clinical prognostic marker needs to be established in fur-
ther studies reappraising its transferability to biopsy-based
patient cohorts.
Methods
Patients and clinical endpoint
Test study
A set of 71 FFPE prostate tissue samples from 25 PCa
patients who underwent therapy at the University Hospital
of Bonn in 2011 were included. The samples included 25
PCa, 24 NAT, and 22 BPH specimens.
Patient training cohort
A patient cohort comprised of 498 patients from the TCGA
Research Network. Two Illumina Infinium HumanMethy-
lation450 BeadChip beads (cg12324970 and cg23095743)
were used to calculate relative methylation levels of PITX3
by the formula 100 %*bead_M/(bead_M+ bead_U). The
average value of the ratios of the beads cg12324970 and
cg23095743 was calculated. BCR-free survival was consid-
ered as the primary endpoint of the study. For PITX2,
three Illumina Infinium HumanMethylation450 BeadChip
beads (cg10391633, cg01616926, and cg19134945) were
analyzed, accordingly.
Patient validation cohort
A patient cohort comprised of 300 patients with histo-
logically confirmed PCa who underwent radical prosta-
tectomy at the University Hospital Bonn between 1998
and 2008. BCR-free survival was considered the primary
endpoint of the study and was determined as elevation
PSA levels above 0.2 ng/ml.
Sample preparation
For the analysis of PITX3 methylation, the FFPET sam-
ples were processed according to the InnuCONVERT
Bisulfite All-In-One Kit (Analytik Jena, Germany) as pre-
viously published [10]. To validate the assay perform-
ance, a serial dilution of bisulfite-converted artificially
methylated DNA (CpGenome™ Universal Methylated
DNA; Merck Millipore, Darmstadt, Germany) and
unmethylated DNA from human sperm (NW Andrology
& Cryobank Inc., Spokane, WA, USA) was used. As a
calibrator sample DNA, a 1:1 mixture of bisulfite-
converted unmethylated and artificially methylated DNA
was used.
mPITX2 and mPITX3 quantitative real-time PCR
The DNA methylation of PITX2 and PITX3 was deter-
mined by means of qMSP and QM PCR assays, respect-
ively. The PITX2 qMSP assay has been described earlier
in detail [29]. Table 4 lists the primers and probes used
for the QM PITX3 assay. Each sample was measured in
triplicate with an input of 25 ng bisulfite-converted
DNA per reaction. The PITX3 QM assay was performed
using an AB 7500 Fast Real-Time PCR System (Life
Technologies Corporation, Carlsbad, CA, USA), and the
following temperature profile was used: 15 min at 95 °C
(first denaturation), followed by 45 cycles of 95 °C for
15 s, 60 °C for 2 s, and 55 °C for 60 s. The thresholds
and baselines for analysis were set as follows: 0.02
(threshold) and 3–22 (baseline) for the methylated and
unmethylated probe. mPITX3 was calculated using the
ΔΔCT method:
ΔCT ¼ ΔCTPITX3‐P‐U − ΔCTPITX3‐P‐M; ΔΔCT
¼ ΔCTsample−ΔCTcalibrator; mPITX3




Immunohistochemical staining of ERG and AR was con-
ducted at the Institute of Pathology in Bonn. Staining of
the sections was performed using the LabVision Auto-
stainer 480S system (Thermo Scientific, Waltham, MA,
USA) along with the Thermo Scientific Reagents and the
N-Histofine® DAB-3S detection kit. The AR staining was
Table 4 Primer and probe sequences of the quantitative
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performed as previously described [32]. For the ERG
staining, the following antibody and dilution was used:
clone EPR3864 (Biologo, Kronshagen, Germany; 1:100).
Statistical analyses
The statistical analyses were performed using SPSS, ver-
sion 22 (SPSS Inc., Chicago, IL). The relationship be-
tween input DNA methylation and measured DNA
methylation was assessed by linear regression. State-
ments regarding potential correlations of specific hist-
ology findings were made using the Spearman’s rank
correlation coefficient (ρ). BCR-free survival analyses
were conducted by Kaplan-Meier and univariate Cox
proportional hazards regression analyses. Kaplan-Meier
analysis was conducted using the log-rank test and likeli-
hood ratios (LR). p values lower than 0.05 were consid-
ered significant. For the comparison of independent
groups, Wilcoxon-Mann-Whitney test (for two groups)
and the Kruskal-Wallis test (for more than two groups)
were applied.
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